Shionogi & Co. has said it aims to complete the final-phase clinical trial for its oral COVID-19 drug in December and start supplying it by the end of March next year. The drugmaker will establish by the end of March 2022 a production system that can make doses of the orally taken medicine for at least 1 million people.
S-217622, a therapeutic drug for COVID-19, is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. The new coronavirus (SARS-CoV-2) has an enzyme called 3CL protease, which is essential for the replication of the virus. S-217622 suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease. In non-clinical trials using SARS-CoV-2 infected animals, it has been confirmed that the viral load is rapidly and significantly reduced. Japanese Phase 1 clinical trials began in July 20211, and a Phase 2/3 clinical trial is currently underway in mild or asymptomatic COVID-19 patients.
系统提示：若遇到视频无法播放请点击下方链接
https://www.youtube.com/embed/3tCCofGaSAs
日本制药企业——盐野义制药公司研发制造的新冠病毒治疗口服药，将在未来几个月时间里投入使用。这一款口服药的投入，使得新冠病毒的治疗，趋同于流行性感冒，对于控制疫情的蔓延，将起到十分重要的作用。 盐野义制药公司已有140多年历史，以生产抗菌药为主。
The drugmaker will establish by the end of March 2022 a production system that can make doses of the orally taken medicine for at least 1 million people.
S-217622, a therapeutic drug for COVID-19, is a 3CL protease inhibitor created through joint research between Hokkaido University and Shionogi. The new coronavirus (SARS-CoV-2) has an enzyme called 3CL protease, which is essential for the replication of the virus. S-217622 suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease. In non-clinical trials using SARS-CoV-2 infected animals, it has been confirmed that the viral load is rapidly and significantly reduced. Japanese Phase 1 clinical trials began in July 20211, and a Phase 2/3 clinical trial is currently underway in mild or asymptomatic COVID-19 patients.
扯蛋 送台湾的日本产新冠疫苗打死了多少人
查了一下，中国平安还是第七大股东
算一下 大概估值一千亿人民币 一百多亿美金 就是小药厂吧 看看最近几年药厂的兼并 一百亿不算啥 这两天就有一起百亿级别的
👍
19年初在日本得了A型流感，发烧39度，去了一家小诊所看了医生后就给我开了一种鼻腔吸入的粉末药，只需要吸一次护士看着当场吸入后，就打发我回家了。第二天一早测体温，36.5度，完全好了，虽然一周内都有些疲惫。当时听说这是一种日本自己的新药，依靠抑制病毒复制的原理。
新冠流行后我就想能治流感的技术应该也可以对付新冠吧，果然出来了。
我很少得流感，19年那次之前差不多就是小学2年级的时候了，呵呵。但就是普通感冒，往往都要折腾人一星期左右的。这次这么严重的流感，当时自己非常的痛苦，发冷浑身疼，但结果就吸了一次药，第二天就完全好了！大大地让我吃惊了。
那只能看大大心情了 毕竟香港回国深圳都要隔离 hk可没啥疫情
怎么没有用？没有那么快有用就是因为像你这样科盲又自大的人太多好么
这个更像pfizer在做的那个。如果效果做出来差不多可能这个更好（副作用会小些）
扯淡，之前在药监工作过，日韩标准比中国低
神药有过好几个了，最后结果都不怎么样。这次大家还是谨慎乐观吧。
日韩标准比中国低？？？你在哪个药监待过？？？